Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

Journal of Clinical Oncology

Volumn 28, Issue 14, 2010, Pages 2356-2364

  Wagner, Katharina ^a   Damm, Frederik ^a   Göhring, Gudrun ^a   Görlich, Kerstin ^a   Heuser, Michael ^a   Schäfer, Irina ^a   Ottmann, Oliver ^a   Lübbert, Michael ^a   Heit, Wolfgang ^a   Kanz, Lothar ^a   Schlimok, Günter ^a   Raghavachar, Aruna A ^a   Fiedler, Walter ^a   Kirchner, Hartmut H ^a   Brugger, Wolfram ^a   Zucknick, Manuela ^a   Schlegelberger, Brigitte ^a   Heil, Gerhard ^a   Ganser, Arnold ^a   Krauter, Jürgen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; MESSENGER RNA; NUCLEOPHOSMIN; UNCLASSIFIED DRUG; WT1 PROTEIN; IDH1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLELE; ARTICLE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; GERMANY; KAPLAN MEIER METHOD; KARYOTYPING; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; GENOTYPE; GERMANY; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIERS ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952481300     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.6899     Document Type: Article

References (26)

1. Fröhling S, Scholl C, Gilliland DG, et al: Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 23:6285-6295, 2005 (Pubitemid 46218838)
2. Döhner K, Döhner H: Molecular characterization of acute myeloid leukemia. Haematologica 93:976-982, 2008
3. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005 (Pubitemid 40110814)
4. Fröhling S, Schlenk RF, Breituck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380, 2002 (Pubitemid 35434129)
5. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004 (Pubitemid 41095065)
6. Gaidzik VI, Schlenk RF, Moschny S, et al: Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: A study of the German-Austrian AML Study Group. Blood 113:4505-4511, 2009
7. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008
8. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005 (Pubitemid 41739007)
9. Paschka P, Marcucci G, Ruppert AS, et al: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study. J Clin Oncol 26:4595-4602, 2008
10. Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066, 2009
11. Sanson M, Marie Y, Paris S, et al: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154, 2009
12. Yan H, Parsons DW, Jin G, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773, 2009
13. Zhao S, Lin Y, Xu W, et al: Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324:261-265, 2009
14. Damm F, Heuser M, Morgan M, et al: Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 28:578-585, 2010
15. Heil G, Krauter J, Raghavachar A, et al: Risk-adapted induction and consolidation therapy in adults with de novo AML aged ≤ 60 years: Results of a prospective multicenter trial. Ann Hematol 83:336-344, 2004 (Pubitemid 38684445)
16. Krauter J, Wagner K, Schafer I, et al: Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: Individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 27:3000-3006, 2009
17. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
18. Korn EL: Censoring distributions as a measure of follow-up in survival analysis. Stat Med 5:255-260, 1986
19. Kang MR, Kim MS, Oh JE, et al: Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer 125:353-355, 2009
20. Mueller BU, Pabst T, Osato M, et al: Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100:998-1007, 2002 (Pubitemid 34832629)
21. Döhner K, Tobis K, Bischof T, et al: Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: A study of the AML Study Group Ulm (AMLSG ULM). Blood 102:3850, 2003
22. Neubauer A, Maharry K, Mrozek K, et al: Patients with acute myeloid leukemia and RAS mutations benefit most from postremission highdose cytarabine: A Cancer and Leukemia Group B study. J Clin Oncol 26:4603-4609, 2008
23. Komar AA: Silent SNPs: Impact on gene function and phenotype. Pharmacogenomics 8:1075-1080, 2007
24. Hoffmeyer S, Burk O, von Richter O, et al: Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473-3478, 2000 (Pubitemid 30183327)
25. Kimchi-Sarfaty C, Oh JM, Kim IW, et al: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528, 2007
26. Skokowa J, Lan D, Thakur BK, et al: NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat Med 15:151-158, 2009